Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50. doi: 10.1016/s0960-894x(02)01020-x.

Abstract

The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-alpha and IL-1 beta. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-alpha in vivo.

MeSH terms

  • Catalysis
  • Enzyme Inhibitors / chemical synthesis*
  • Enzyme Inhibitors / pharmacology*
  • Imidazoles / chemical synthesis*
  • Imidazoles / pharmacology*
  • Indicators and Reagents
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • Pyrimidines / chemical synthesis
  • Pyrimidines / pharmacology
  • Structure-Activity Relationship
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Enzyme Inhibitors
  • Imidazoles
  • Indicators and Reagents
  • Pyrimidines
  • Tumor Necrosis Factor-alpha
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases